Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of de Novo Acute Myeloid Leukemia With the Combination of Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin (Mylotarg ®), Associated or Not Priming With G-CSF. Prospective Study of Efficacy and Toxicity

NCT01698879 is registered in ClinicalTrials.gov with Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias as lead sponsor.

NCT NCT01698879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01698879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of de Novo Acute Myeloid Leukemia With the Combination of Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin (Mylotarg ®), Associated or Not Priming With G-CSF. Prospective Study of Efficacy and Toxicity
Lead sponsor
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2009
Completion date
September 26, 2016
Enrollment
46 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

novo acute myeloid leukemia